PLCXD3 and metabolic dysfunction-associated steatotic liver disease: These outcomes were consistent with the literature review, which suggested that up-regulated PLCXD3 might contribute to the progression of NAFLD and AS due to its involvement in hyperinsulinemia and dyslipidemia.